Introduction: Fatigue and cognitive deficits are common symptoms affecting patients with multiple sclerosis.
Methods: The effects of interferon beta on fatigue and cognitive deficits were assessed in 50 patients with relapsing multiple sclerosis (recruited at a single center). The pre-treatment assessments were performed on visits 1 and 2 (Months 0 and 3). Patients started treatment with subcutaneous interferon beta-1a or beta-1b, or intramuscular interferon beta-1a at Month 3, with reassessment at visits 3 and 4 (6 and 12 months, respectively). Co-primary endpoints were change in fatigue (Modified Fatigue Impact Scale) and change in cognition (Brief Repeatable Battery of Neuropsychological Tests) from pre-treatment to visits 3 and 4. Follow-up data were obtained for 40 patients.
Results: The pre-treatment demographic and disease characteristics did not differ between groups. Improvements in fatigue levels were reported for patients receiving subcutaneous interferon beta-1a versus patients in the intramuscular interferon beta-1a group (p = .04) and in the interferon beta-1b group (p = .09). Improvements were also reported in five out of 17 cognitive indices for all the treatment groups.
Conclusion: The data suggest that interferon beta may reduce fatigue and cognitive deficits in patients with relapsing multiple sclerosis. Larger, randomized, and controlled studies are required to confirm our findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00207454.2010.511732 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiple Sclerosis-like Lesions Induced by Radiation: A Case Report and Systematic Review of the Literature.
J Clin Med
December 2024
Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Radiotherapy (RT) remains crucial in treating both primary and metastatic central nervous system cancer. Despite advancements in modern techniques that mitigate some toxic adverse effects, magnetic resonance imaging (MRI) scans still reveal a wide range of radiation-induced changes. Radiation can adversely affect neuroglial cells and their precursors, potentially triggering a demyelinating pattern similar to multiple sclerosis (MS).
View Article and Find Full Text PDFSectm1a Depletion Promotes Neutrophil Recruitment during Pneumococcal Pneumonia.
Am J Respir Cell Mol Biol
December 2024
Keio University School of Medicine, Division of Pulmonary Medicine, Department of Medicine, Tokyo, Japan.
Airway epithelial cells (AECs) play an essential role in the immune response during bacterial pneumonia. Secreted and transmembrane 1a (Sectm1a) is specifically expressed in AECs during early (SP) infection. However, its function remains largely unexplored.
View Article and Find Full Text PDFInfection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study.
Clin Pharmacol Ther
November 2024
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas, USA.
In patients with multiple sclerosis (MS), infections represent a significant concern, particularly given the immunomodulatory effects of disease-modifying agents (DMAs). High-efficacy DMAs (heDMAs) play a pivotal role in delaying MS progression, yet their use also raises concerns regarding the risk of infection. This study aimed to compare the infection risk with the use of heDMA and moderate-efficacy disease-modifying agents (meDMAs) in MS patients.
View Article and Find Full Text PDFModulation of persistent bladder pain in mice: The role of macrophage migration inhibitory factor, high mobility group box-1, and downstream signaling pathways.
Bladder (San Franc)
October 2024
Lexington VA Health Care System, Research and Development, Lexington, KY, USA.
Background: Repeated intravesical activation of protease-activated receptor-4 (PAR4) serves as a model of persistent bladder hyperalgesia (BHA) in mice, which lasts several days after the final stimulus. Spinal macrophage migration inhibitory factor (MIF) and high mobility group box 1 (HMGB1) are critical mediators in the persistence of BHA.
Objective: We aimed to identify effective systemic treatments for persistent BHA using antagonists or transgenic deletions.
Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis.
Ther Adv Neurol Disord
October 2024
Department of Neurology, Focus Program Translational Neuroscience, Rhine-Main Neuroscience Network, University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstrasse 1, Mainz 55131, Germany.
Article Synopsis
- Interferon-beta (IFN-β) remains crucial for managing multiple sclerosis (MS), with pegylated (PEG) IFN-β offering less frequent dosing for patients with relapsing-remitting MS (RRMS).
- A study examined laboratory results and side effects between two forms of IFN-β treatment (PEG-IFN-β-1a and IFN-β-1a) among patients with clinically isolated syndrome (CIS) or RRMS over nine years.
- Findings indicated that PEG-IFN-β-1a led to lower leukocyte counts and higher rates of leukopenia and neutropenia compared to IFN-β-1a, though both treatments had similar disease activity outcomes
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!